Leverette (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol / Levonorgestrel, the active ingredient in Leverette, is a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It works to prevent pregnancy by inhibiting ovulation, thickening cervical mucus and altering the endometrial lining in women of reproductive age.

GNH USA supplies Leverette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this hormonal contraceptive for qualified prescribers. The company adheres to EU quality standards and offers comprehensive logistics support for global distribution.

Leverette, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception.

- Prevention of pregnancy: provides reliable reversible contraception for women of reproductive age. - Family planning: enables planned intervals between pregnancies. - Hormonal contraception: suppresses ovulation and modifies cervical mucus to reduce fertilisation risk.

Leverette may cause a range of adverse reactions. The frequency and severity vary among individuals.

Common Side Effects: - Nausea: mild to moderate stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: occasional mild to moderate headache. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Mood changes: mild fluctuations in mood or emotional state. - Weight fluctuation: slight changes in body weight or fluid retention.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism, particularly in high‑risk individuals. - Hypertension: new‑onset or worsening high blood pressure. - Hepatic adenoma: rare benign liver tumor. - Visual disturbances: sudden loss of vision or eye pain. - Severe allergic reaction: anaphylaxis, rash, or swelling of the face and throat. - Cardiovascular events: myocardial infarction or stroke in susceptible patients.

Before prescribing Leverette, clinicians should evaluate patient history and risk factors. - Cardiovascular risk assessment: avoid in women with a history of thromboembolism or uncontrolled hypertension. - Smoking status: contraindicated for smokers over 35 years of age. - Liver function: assess hepatic disease, as metabolism may be impaired. - Pregnancy contraindication: do not use during known or suspected pregnancy. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Leverette can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness. - Rifampicin or other rifamycins: strong induction of hepatic enzymes can lower hormone levels. - St. John's wort: herbal inducer that can compromise contraceptive reliability.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly diminish contraceptive effect. - Antifungal agents (e.g., fluconazole): can increase hormone concentrations, raising side‑effect risk. - Antiretroviral drugs (e.g., protease inhibitors): may alter hormone metabolism, requiring clinical monitoring.